EFFECT OF PITHECELLOBIUM DULCE BENTH LEAVES IN DEXAMETHASONE INDUCED DIABETIC RATS

Objective: The objective of the present study was to study the effect of Pithecellobium dulce Benth (P. dulce) leaves in dexamethasone-induced diabetic rats.Methods: The authenticated P. dulce leaves were collected from a local area of Sangli, Maharashtra. The leaves of the plant were extracted with water and ethanol by maceration and soxhelation respectively. Acute toxicity studies of the both extracts were performed using rat and according to OECD 425 guidelines. The dose of 200 mg/kg and 400 mg/kg was selected for further studies. The albino rats were divided into seven groups with five animals in each group. The diabetes was induced by dexamethasone (10 mg/kg, s. c.) and treated with extract and standard drug for 10 d. Then blood glucose, triglyceride, total cholesterol and glycogen level in liver, muscle and kidney were estimated according to standard procedures.Results: The study revealed that P. dulce at 200 mg/kg and 400 mg/kg showed significant (p Ë‚ 0.05) antidiabetic activity. All the extract treated groups showed a significant reduction in blood glucose level on 11th day when compared to diabetic control group. The significant increase in blood glucose, triglyceride, and total cholesterol level was observed in the diabetic control group when compared to normal control group. The liver and muscle glycogen level was decreased significantly (p Ë‚ 0.05) in the diabetic control group.Conclusion: It can be concluded that P. dulceaqueous and ethanolic extract at two different doses (200 mg/kg and 400 mg/kg) possesses antidiabetic and hypolipidemic activity.Â

Addition of some non-indigenous elements to the flora of Marathwada regions, Maharashtra, India.

During our field survey, many taxa were collected from the Marathwada region. Specimens were brought to laboratory and processed for herbarium specimens with standard procedures. Majority of the specimens satisfactory identified by using pertinent literature. After critical investigations, authors found that six taxa are not earlier reported from the region. So present paper deals new records of six species with its correct and updated citation, short description and note on its phenology is depicted for each taxon followed by a note on ecology and images of all for easy identification

Costus pictus D.Don.ex Lindl. new records to flora of Maharashtra, India.

During the field survey in Paithan Tehshil of Aurangabad District some Specimens were collected and identified Costus pictus D.Don ex Lindl which was not recorded for Flora of Maharashtra so far. This paper records them with updated nomenclature, descriptions and note on phenology and Images for its easy identity

BILATERAL RENAL ARTERY STENOSIS IN A HYPERTENSIVE LUPUS PATIENT WITHOUT RENAL DYSFUNCTION: A CASE REPORT

Systemic lupus erythematosus (SLE) is associated with a high prevalence of atherosclero-sis and an enhanced cardiovascular mortality. In adult subjects, several studies have shown the coexistence of SLE and renal artery stenosis, most of them with unilateral in-volvement or with renal dysfunction. We observed a 62-year-old man with SLE and a 10-year history of moderate-to-severe hy-pertension who was admitted to our hospital because of uncontrolled blood pressure val-ues (152/95 mmHg), despite drug therapy. No signs of renal impairment were evident. After an initial physical examination, which presented a periumbilical bruit, a renal ultra-sound was performed with evidence of bilateral renal artery stenosis. An angio-MR study also confirmed the diagnosis and showed a double renal artery on the right side. Many different factors can contribute to the bilateral renal artery stenosis in this patient. Chronic inflammatory state associated to SLE, metabolic alterations with dyslipidemia and steroid therapy may all be involved in the development of the renal atherosclerotic le-sions

Self-assembly into liquid crystalline complex through intermolecular hydrogen bonding

525-52

Synthesis and Pharmacological Evaluation of Pyrazoline and Pyrimidine Analogs of Combretastatin-A4 as Anticancer, Anti-inflammatory and Antioxidant Agents

A library of 3,5-diaryl-1-carbothioamide-pyrazoline (5a–j), N1-phenyl sulfonyl pyrazoline (6a–e) and pyrimidine (7a) analogs of combretastatin-A4 were synthesized and evaluated for their in vitro anticancer, anti-inflammatory and antioxidant activity. Results of in vitro assay against human breast cancer cell line (MCF-7) showed several compounds endowed with significant cytotoxicity compared to the adriamycin, a standard anticancer drug. Among the compounds synthesized, 7a was found to possess significant antiproliferative activity (GI50 < 0.1 µM) against the MCF-7 cell line as good as adriamycin (GI50 < 0.1 µM) whereas, compounds 6c, 5j and 5g also displayed good cytotoxicity (GI50 = 25.3–42.6 µM). Besides this, most active compound 7a was also evaluated against human myeloid leukemia cell line K562 and the remarkable result was obtained with GI50 < 0.1 µM, comparable to that of adriamycin (GI50 < 0.1 µM). In addition, all the synthesized compounds were evaluated for their anti-inflammatory and antioxidant activity. The percent inhibition studies revealed that most of the compounds were found to possess substantial anti-inflammatory and antioxidant activities. This work is licensed under a Creative Commons Attribution 4.0 International License

Absence of an independent association between serum uric acid and left ventricular mass in Caucasian hypertensive women and men

Background and aim: Experimentally uric acid may induce cardiomyocyte growth and interstitial fibrosis of the heart. However, clinical studies exploring the relationship between serum uric acid (SUA) and left ventricular (LV) mass yielded conflicting results. The aim of our study was to evaluate the relationships between SUA and LV mass in a large group of Caucasian essential hypertensive subjects. Methods and results: We enrolled 534 hypertensive patients free of cardiovascular complications and without severe renal insufficiency. In all subjects routine blood chemistry, including SUA determination, echocardiographic examination and 24 h ambulatory blood pressure (BP) monitoring were obtained. In the overall population we observed no significant correlation of SUA with LV mass indexed for height2.7 (LVMH2.7) (r = 0.074). When the same relationship was analysed separately in men and women, we found a statistically significant correlation in female gender (r = 0.27; p < 0.001), but not in males (r = 0.042; p = NS). When we grouped the study population in sex-specific tertiles of SUA, an increase in LVMH2.7 was observed in the highest tertiles in women (44.5 \ub1 15.6 vs 47.5 16 vs 55.9 \ub1 22.2 g/m2.7; p < 0.001), but not in men. The association between SUA and LVMH2.7 in women lost statistical significance in multiple regression analyses, after adjustment for age, 24 h systolic BP, body mass index, serum creatinine and other potential confounders. Conclusions: Our findings do not support an independent association between SUA and LV mass in Caucasian men and women with arterial hypertension

Finding needles in haystacks: linking scientific names, reference specimens and molecular data for Fungi

DNA phylogenetic comparisons have shown that morphology-based species recognition often underestimates fungal diversity. Therefore, the need for accurate DNA sequence data, tied to both correct taxonomic names and clearly annotated specimen data, has never been greater. Furthermore, the growing number of molecular ecology and microbiome projects using high-throughput sequencing require fast and effective methods for en masse species assignments. In this article, we focus on selecting and re-annotating a set of marker reference sequences that represent each currently accepted order of Fungi. The particular focus is on sequences from the internal transcribed spacer region in the nuclear ribosomal cistron, derived from type specimens and/or ex-type cultures. Re-annotated and verified sequences were deposited in a curated public database at the National Center for Biotechnology Information (NCBI), namely the RefSeq Targeted Loci (RTL) database, and will be visible during routine sequence similarity searches with NR_prefixed accession numbers. A set of standards and protocols is proposed to improve the data quality of new sequences, and we suggest how type and other reference sequences can be used to improve identification of Fungi

Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience

The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). This strategy allows almost 50% of patients to be cured. Post-ASCT maintenance treatment with brentuximab vedotin (BV) confers improved progression-free survival (PFS) to cHL patients at high risk of relapse. We investigated the outcome of 105 cHL patients receiving post-ASCT BV maintenance in the real-life setting of 23 Italian hematology centers. This population included naïve patients and those previously exposed to BV. Median follow-up was 20 months. Patients presented a median of two lines of treatment pre-ASCT, with 51% receiving BV. Twenty-nine percent of patients had at least two high-risk factors (refractory disease, complete response [CR] less than 12 months, extranodal disease at relapse), while 16% presented none. At PET-CT, a Deauville score (DS) of 1–3 was reported in 75% and 78% of pre- and post-ASCT evaluations, respectively. Grade 3–4 adverse events (AEs), mainly peripheral neuropathy, were observed in 16% of patients. Three-year PFS and overall survival (OS) were 62% and 86%, respectively. According to BV exposure, 3-year PFS and OS were 54% and 71%, respectively, for naïve and 77% and 96%, respectively, for previously exposed patients. Refractory disease (hazard ratio [HR] 4.46; p&nbsp;=&nbsp;0.003) and post-ASCT DS 4–5 (HR 3.14; p&nbsp;=&nbsp;0.005) were the only two factors significantly associated with PFS reduction in multivariable analysis. Post-ASCT BV maintenance is an effective, safe treatment option for cHL naïve patients and those previously exposed to BV

CALR MUTATIONS IN SICILIAN ESSENTIAL THROMBOCYTHEMIA AND MYELOFIBROSIS PATIENTS.

Background. Essential thrombocythemia (ET) and primary myelofibrosis (MF) are myeloproliferative neoplasms characterized by the overproduction of mature cells such as platelets (ET) or early bone marrow fibrosis due to scarring induced by highly proliferating myeloid progenitors and pathological stimulation of local fibroblasts (MF). Somatic mutations in CALR gene have recently identified in the majority of JAK2-V617F and MPL negative ET and MF patients. In this study we evaluated the frequency and type of CALR mutations and their clinical and hematological features. Methods. A total of 54 patients, 29 ET and 25 MF patient, was included in this study. All patients were JAK2 V617F and MPL negative. We registered clinical and hematological characteristics of patients i.e. age, hemoglobin level, white blood cell count, platelet count, International Prognostic Scoring System (IPSS), risk of thrombosis. Samples were collected from peripheral blood and DNA was extracted by using the QIAamp DNA mini kit (QIAGEN); CALR mutations were analyzed by direct sequencing method. Results. CALR mutations were present in 20.4 % of patients (4 ET; 7 MF). Four types of CALR mutations were detected; type 1 (p.L367fs*46) was isolated in 6 MF patient, type 2 (p.K385fs*47) was isolated in 3 ET patient; we also found 2 deletion mutations (p.E371fs*49 and D373fs*47), which are less common deletions, in the remaining patients. Patients carrying CALR mutations were younger (mediane age: 50 vs 65; p=0.2) than CALR negative patients. Furthermore, they did not show thrombosis and IPSS high risk. Conclusions. Our observations are in agreement with the findings of literature. We can assert an improved outcome of CALR mutated patients and we can also speculate a possible protective role of CARL mutations given the absence of thrombosis events and of IPSS high risk. However, the cohort of patients with myeloproliferative disease need to be implemented to draw final conclusion